[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8748101A1 - Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus - Google Patents

Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Info

Publication number
PA8748101A1
PA8748101A1 PA20078748101A PA8748101A PA8748101A1 PA 8748101 A1 PA8748101 A1 PA 8748101A1 PA 20078748101 A PA20078748101 A PA 20078748101A PA 8748101 A PA8748101 A PA 8748101A PA 8748101 A1 PA8748101 A1 PA 8748101A1
Authority
PA
Panama
Prior art keywords
treatment
disease
compounds
preparation
oxazolopiridins
Prior art date
Application number
PA20078748101A
Other languages
English (en)
Inventor
Gerspacher Marc
Furet Pascal
Vangrevelinghe Eric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8748101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8748101A1 publication Critical patent/PA8748101A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE BENZOXAZOL 2,7-DISUSTITUIDO Y OXAZOLO-[5,4-C]-PIRIDINA 2,4-DISUSTITUIDA DE LA FORMULA I QUE SE DA MAS ADELANTE, ASI COMO A SALES DE LOS MISMOS, A PROCESOS PARA SU PREPARACION, A LA APLICACION DE LOS MISMOS EN UN PROCESO PARA EL TRATAMIENTO DEL CUERPO HUMANO O ANIMAL, ESTOS COMPUESTOS PARA UTILIZARSE EN EL TRATAMIENTO (INCLUYENDO PROFILAXIS) DEL CUERPO DEL ANIMAL, EN ESPECIAL HUMANO (ESPECIALMENTE CON RESPECTO A UNA ENFERMEDAD PROLIFERATIVA), EL USO DE LOS MISMOS - SOLOS O EN COMBINACION CON UNO O MAS COMPUESTOS FARMACEUTICAMENTE ACTIVOS DIFERENTES - PARA EL TRATAMIENTO EN ESPECIAL DE UNA ENFERMEDAD MEDIADA POR LA CINASA DE PROTEINA TIROSINA (TAL COMO UNA ENFERMEDAD TUMORAL) O PARA LA FABRICACION DE UNA PREPARACION FARMACEUTICA PARA UTILIZARSE EN EL TRATAMIENTO DE ESTA ENFERMEDAD, UN METODO PARA EL TRATAMIENTO DE ESTA ENFERMEDAD Y UNA PREPARACION FARMACEUTICA PARA EL TRATAMIENTO DE UNA ENFERMEDAD COMO SE MENCIONA. LOS COMPUESTOS SON DE LA FORMULA I: EN DONDE LOS SIMBOLOS SON COMO SE DEFINEN EN LA DESCRIPCION. LOS COMPUESTOS INHIBEN, POR EJEMPLO, JAK2 Y JAK3.
PA20078748101A 2006-09-15 2007-09-14 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus PA8748101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Publications (1)

Publication Number Publication Date
PA8748101A1 true PA8748101A1 (es) 2009-08-26

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078748101A PA8748101A1 (es) 2006-09-15 2007-09-14 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Country Status (30)

Country Link
US (1) US8629168B2 (es)
EP (2) EP1900729A1 (es)
JP (1) JP5325105B2 (es)
KR (1) KR20090064389A (es)
CN (1) CN101516860B (es)
AR (1) AR062786A1 (es)
AT (1) ATE532774T1 (es)
AU (1) AU2007296916B2 (es)
BR (1) BRPI0716841A2 (es)
CA (1) CA2660987A1 (es)
CL (1) CL2007002669A1 (es)
CO (1) CO6150142A2 (es)
CR (1) CR10639A (es)
EA (1) EA200900388A1 (es)
ES (1) ES2377148T3 (es)
GT (1) GT200900056A (es)
IL (1) IL196860A0 (es)
MA (1) MA30723B1 (es)
MX (1) MX2009002812A (es)
NO (1) NO20091469L (es)
PA (1) PA8748101A1 (es)
PE (1) PE20080842A1 (es)
PL (1) PL2066647T3 (es)
PT (1) PT2066647E (es)
SM (1) SMP200900023B (es)
TN (1) TN2009000070A1 (es)
TW (1) TW200819444A (es)
UY (1) UY30587A1 (es)
WO (1) WO2008031594A1 (es)
ZA (1) ZA200900477B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP3009436B1 (en) 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
NZ590377A (en) * 2008-07-15 2011-11-25 Sanofi Aventis Oxazolopyrimidines as edg-1 receptor agonists
TW201010977A (en) * 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN102227409B (zh) 2008-11-28 2014-03-26 兴和株式会社 吡啶-3-甲酰胺衍生物
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
TWI485153B (zh) * 2010-01-13 2015-05-21 Sanofi Aventis 2,5,7-經取代唑并嘧啶衍生物
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
TWI665178B (zh) 2015-08-03 2019-07-11 夸德里加生物科學公司 作為化療劑的β-取代的β-氨基酸和類似物及其應用
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229671B1 (en) * 1999-12-10 2014-04-28 Pfizer Prod Inc Pyrrolo[2,3-d]pirimidine compounds
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
AU2006286573B2 (en) * 2005-09-02 2012-05-31 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
KR20090031787A (ko) * 2006-07-21 2009-03-27 노파르티스 아게 Jak 키나제 억제제로서의 2,4-디(아릴아미노)-피리미딘-5-카르복스아미드 화합물

Also Published As

Publication number Publication date
JP2010503629A (ja) 2010-02-04
US20100009978A1 (en) 2010-01-14
CA2660987A1 (en) 2008-03-20
NO20091469L (no) 2009-04-15
KR20090064389A (ko) 2009-06-18
JP5325105B2 (ja) 2013-10-23
TW200819444A (en) 2008-05-01
US8629168B2 (en) 2014-01-14
PE20080842A1 (es) 2008-08-11
EP2066647B1 (en) 2011-11-09
WO2008031594A1 (en) 2008-03-20
IL196860A0 (en) 2009-11-18
AU2007296916A1 (en) 2008-03-20
UY30587A1 (es) 2008-05-02
SMP200900023B (it) 2009-07-14
CL2007002669A1 (es) 2008-05-09
ATE532774T1 (de) 2011-11-15
EP1900729A1 (en) 2008-03-19
PT2066647E (pt) 2012-01-17
EP2066647A1 (en) 2009-06-10
CO6150142A2 (es) 2010-04-20
GT200900056A (es) 2011-11-08
PL2066647T3 (pl) 2012-04-30
CN101516860B (zh) 2012-06-27
EA200900388A1 (ru) 2009-08-28
MX2009002812A (es) 2009-03-31
ES2377148T3 (es) 2012-03-22
BRPI0716841A2 (pt) 2013-10-01
AU2007296916B2 (en) 2011-10-06
SMAP200900023A (it) 2009-05-11
ZA200900477B (en) 2010-01-27
MA30723B1 (fr) 2009-09-01
CN101516860A (zh) 2009-08-26
TN2009000070A1 (en) 2010-08-19
CR10639A (es) 2009-07-03
AR062786A1 (es) 2008-12-03

Similar Documents

Publication Publication Date Title
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
PA8680701A1 (es) Derivados de oxindol
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
UY29246A1 (es) Nuevos compuestos
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP10010427A (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
UY29300A1 (es) Compuestos quimicos
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
GT200600089A (es) Compuestos organicos
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor